Ibandronate sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
HazMat Fee +
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Ibandronate Sodium Monohydrate is a potent nitrogen-containing bisphosphonate, primarily utilized in the treatment of osteoporosis. It operates by targeting the bone metabolism to prevent bone loss. In research focused on endothelial cells, Ibandronate at concentrations between 1.25 and 2 μM notably reduces cell growth. At 2 μM, it also significantly hampers the formation of capillary-like structures and induces apoptosis in these cells. Furthermore, Ibandronate increases VEGF expression in endothelial cells in a dose-dependent manner when administered at concentrations below 100 μM[1]. In studies involving prostate cancer cell lines, including LNCaP and PC-3, Ibandronate shows a dose-dependent inhibitory effect on cell growth at concentrations below 100 μM[2]. For clinical applications in osteoporosis, Ibandronate administered daily at 2.5 mg or intermittently at 20 mg every other day for 12 doses every three months, significantly reduces the risk of new morphometric vertebral fractures by 62% and 50%, respectively, over a period of three years. Additionally, these dosing regimens lead to a significant and progressive increase in bone mineral density (BMD) of the lumbar spine by 6.5% and 5.7%, respectively, in osteoporotic women following three years of treatment[3]. In ovariectomized rats, a model for post-menopausal osteoporosis, Ibandronate administered subcutaneously at doses up to 125 mg/kg results in a dose-dependent increase in bone mineral density, trabecular bone volume, trabecular number, maximum load to failure (Fmax), and yield load in long bones and vertebrae. It also fully prevents the increase in trabecular separation observed in these rats[4].
搜索
HazMat Fee +
